Browse > Article
http://dx.doi.org/10.4062/biomolther.2015.041

Measurement of Human Cytochrome P450 Enzyme Induction Based on Mesalazine and Mosapride Citrate Treatments Using a Luminescent Assay  

Kim, Young-Hoon (Pharmacological Research Division, Toxicological and Research Department, National Institute of Food and Drug Safety Evaluation, Ministry of Food and Drug safety)
Bae, Young-Ji (Pharmacological Research Division, Toxicological and Research Department, National Institute of Food and Drug Safety Evaluation, Ministry of Food and Drug safety)
Kim, Hyung Soo (Pharmacological Research Division, Toxicological and Research Department, National Institute of Food and Drug Safety Evaluation, Ministry of Food and Drug safety)
Cha, Hey-Jin (Pharmacological Research Division, Toxicological and Research Department, National Institute of Food and Drug Safety Evaluation, Ministry of Food and Drug safety)
Yun, Jae-Suk (Pharmacological Research Division, Toxicological and Research Department, National Institute of Food and Drug Safety Evaluation, Ministry of Food and Drug safety)
Shin, Ji-Soon (Pharmacological Research Division, Toxicological and Research Department, National Institute of Food and Drug Safety Evaluation, Ministry of Food and Drug safety)
Seong, Won-Keun (Pharmacological Research Division, Toxicological and Research Department, National Institute of Food and Drug Safety Evaluation, Ministry of Food and Drug safety)
Lee, Yong-Moon (College of Pharmacy, Chungbuk National University)
Han, Kyoung-Moon (Pharmacological Research Division, Toxicological and Research Department, National Institute of Food and Drug Safety Evaluation, Ministry of Food and Drug safety)
Publication Information
Biomolecules & Therapeutics / v.23, no.5, 2015 , pp. 486-492 More about this Journal
Abstract
Drug metabolism mostly occurs in the liver. Cytochrome P450 (CYP) is a drug-metabolizing enzyme that is responsible for many important drug metabolism reactions. Recently, the US FDA and EU EMA have suggested that CYP enzyme induction can be measured by both enzymatic activity and mRNA expression. However, these experiments are time-consuming and their interassay variability can lead to misinterpretations of the results. To resolve these problems and establish a more powerful method to measure CYP induction, we determined CYP induction by using luminescent assay. Luminescent CYP assays link CYP enzyme activity to firefly luciferase luminescence technology. In this study, we measured the induction of CYP isozymes (1A2, 2B6, 2C9, and 3A4) in cryopreserved human hepatocytes (HMC424, 478, and 493) using a luminometer. We then examined the potential induction abilities (unknown so far) of mesalazine, a drug for colitis, and mosapride citrate, which is used as an antispasmodic drug. The results showed that mesalazine promotes CYP2B6 and 3A4 activities, while mosapride citrate promotes CYP1A2, 2B6, and 3A4 activities. Luminescent CYP assays offer rapid and safe advantages over LC-MS/MS and qRT-PCR methods. Furthermore, luminescent CYP assays decrease the interference between the optical properties of the test compound and the CYP substrates. Therefore, luminescent CYP assays are less labor intensive, rapid, and can be used as robust tools for high-throughput CYP screening during early drug discovery.
Keywords
CYP; Human hepatocytes; Luminescent assay; Mesalazine; Mosapride citrate;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Auld, D. S., Veith, H. and Cali, J. J. (2013) Bioluminescent assays for cytochrome CYP enzymes. Methods Mol. Biol. 987, 1-9.   DOI
2 Bosetti, A., Sobol, M., Ma, D., Good T., Liu, D. and Cali, J. J. (2005) Bioluminescent cytochrome CYP assays. Pharmacologyonline 3, 9-18.
3 Cali, J. J., Ma, D., Sobol, M., Simpson, D. J., Frackman, S., Good, T. D., Daily, W. J. and Liu, D. (2006) Luminogenic cytochrome CYP assays. Expert Opin. Drug Metab. Toxicol. 2, 629-645.   DOI
4 Cali, J. J., Niles, A., Valley, M. P., O'Brien, M. A., Riss, T. L. and Shultz, J. (2008) Bioluminescent assays for ADMET. Expert Opin. Drug Metab. Toxicol. 4, 103-120.   DOI   ScienceOn
5 Garcia, M. C., Ma, D., Dicioccio, A. T. and Cali, J. (2008) The use of a high-throughput luminescent method to assess CYP3A enzyme induction in cultured rat hepatocytes. In Vitro Cell. Dev. Biol. Anim. 44, 129-134.   DOI
6 Kim, S. H., Park, Y. S., Kim, J. M., Park, H. J., Lee, M. H., Park, H. K., Kim, Y. J., Cho, S. H., Shaw, L. M. and Kang, J. S. (2012) Pharmacokinetic and bioavailability studies of 5 mg mosapride tablets in healthy Korean volunteers. Int. J. Clin. Pharmacol. Ther. 50, 524-531.
7 Mann, H. J. (2006) Drug-associated disease: cytochrome CYP interactions. Crit. Care Clin. 22, 329-345, vii.   DOI
8 Ofotokun, I. (2005) Sex differences in the pharmacologic effects of antiretroviral drugs: potential roles of drug transporters and phase 1 and 2 metabolizing enzymes. Top. HIV Med. 13, 79-83.
9 Ogu, C. C. and Maxa, J. L. (2000) Drug interactions due to cytochrome CYP. Proc. (Bayl. Univ. Med. Cent.) 13, 421-423.
10 Parkinson, A., Mudra, D. R., Johnson, C., Dwyer, A. and Carroll, K. M. (2004). The effects of gender, age, ethnicity, and liver cirrhosis on cytochrome CYP enzyme activity in human liver microsomes and inducibility in cultured human hepatocytes. Toxicol. Appl. Pharmacol. 199, 193-209.   DOI
11 Wiersma, H., Escher, J. C., Dilger, K., Trenk, D., Benninga, M. A., van Boxtel, C. J. and Taminiau, J. (2004) Pharmacokinetics of mesalazine pellets in children with inflammatory bowel disease. Inflamm. Bowel Dis. 10, 626-631.   DOI
12 Wrighton, S. A. and Stevens, J. C. (1992) The human hepatic cytochromes CYP involved in drug metabolism. Crit. Rev. Toxicol. 22, 1-21.   DOI
13 Zanger, U. M. and Schwab, M. (2013) Cytochrome CYP enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol. Ther. 138, 103-141.   DOI